Abstract |
Two trials of chlorprothixene were carried out, mainly on patients with moderate to severe post-herpetic neuralgia. When the drug was given as 50 mg b.d. to outpatients, unpleasant side-effects were more important than slight effects in alleviating pain. When the drug was given as 50 mg 6 hourly to inpatients for 5 days only, there was alleviation of constant chronic pain in a third of the patients; the effect is still lasting over a period of months in a few patients. The side-effects during the course of treatment are prominent. It is concluded that the drug is worth trying in the course recommended by Farber and Burks [1] when other means of controlling postherpetic neuralgia have failed. It would be best to give the course only to inpatients.
|
Authors | P W Nathan |
Journal | Pain
(Pain)
Vol. 5
Issue 4
Pg. 367-371
(Dec 1978)
ISSN: 0304-3959 [Print] United States |
PMID | 368703
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
|
Topics |
- Chlorprothixene
(adverse effects, therapeutic use)
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Double-Blind Method
- Herpes Zoster
(complications)
- Humans
- Neuralgia
(drug therapy)
- Pain, Intractable
(drug therapy)
- Phantom Limb
(drug therapy)
- Reflex Sympathetic Dystrophy
(drug therapy)
- Syringomyelia
(drug therapy)
- Thalamus
(physiopathology)
|